Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: acceptance (50), charity (261)

Impaired glucose tolerance in cystic fibrosis - patient information

Description: This factsheet is about impaired glucose tolerance (IGT) in people with cystic fibrosis (CF).
Url: /Media/UHS-website-2019/Patientinformation/Medicinestherapiesandanaesthetics/Impaired-glucose-tolerance-in-cystic-fibrosis-2636-PIL.pdf

Two-hour glucose tolerance test - patient information

Description: Your doctor has recommended that you have a glucose tolerance test. This factsheet aims to answer some of the initial questions
Url: /Media/UHS-website-2019/Patientinformation/Tests/Two-hour-glucose-tolerance-test-738-PIL.pdf

Four hour oral glucose tolerance test - patient information

Description: Your doctor has recommended that you have a prolonged (four hour) oral glucose tolerance test. This factsheet aims to answer some
Url: /Media/UHS-website-2019/Patientinformation/Tests/Four-hour-oral-glucose-tolerance-test-737-PIL.pdf

Two-hour oral glucose tolerance test - patient information

Description: Your doctor has recommended that you have a two-hour oral glucose tolerance test. This factsheet aims to answer some of
Url: /Media/UHS-website-2019/Patientinformation/Tests/Two-hour-oral-glucose-tolerance-test-Acromegaly-735-PIL.pdf

Following your successful food challenge - patient information

Description: This factsheet explains what to expect following your successful food challenge.
Url: /Media/UHS-website-2019/Patientinformation/Digestionandurinaryhealth/Following-your-successful-food-challenge-3264-PIL.pdf

ObinutuzumabVenetoclax LowRisk

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Obinutuzumab-Venetoclax (Low Risk) Regimen • CLL – Obinutuzumab-Venetoclax (Low Risk) Indic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/ObinutuzumabVenetoclax-LowRisk.pdf

Chlorambucil_2_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (2 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (2 day)-Obinutuzu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-2-Obinutuzumab.pdf

Chlorambucil_14_Obinutuzumab

Description: Chemotherapy Protocol Chronic Lymphocytic Leukaemia Chlorambucil (14 day)-Obinutuzumab (6 cycles) Regimen • CLL – Chlorambucil (14 day)-Obinutu
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/Chlorambucil-14-Obinutuzumab.pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description: Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomid
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description: Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamid
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf

1 to 10 of 52

Previous 1 2 3 4 5 … Next